Literature DB >> 23179563

In vivo distribution of 5-Fluorouracil after peritumoral implantation using a biodegradable micro-device in tumor-bearing mice.

Na Zheng1, Mingyao Zhou, Wen Lu.   

Abstract

A novel implantable micro-device was used for delivery of 5-Fluorouracil (5-Fu), which was often used in the treatment of various human malignancies. The biodegradable poly(lactic-co-glycolic) acid (PLGA) was used as material. The purpose of this study was to investigate the efficiency of delivery of 5-Fu to the tumor via this delivery system. The distribution characters of the 5-Fu in tumor, plasma, peritumoral tissue, liver and kidney were compared after peritumoral implantation of micro-device and intraperitoneal injection of solution. After administration of micro-device, the 5-Fu was absorbed into the tumor on Day 1, and Cmax (4.14 μg/g) was reached on Day 6. The half life for the elimination was 4.48 d and the AUC was 46.78 μg × d/g. Similar pharmacokinetic behaviors were observed in plasma, peritumoral tissue, kidney and liver, while the Cmax and the AUC of plasma and these tissues were lower than those of tumor. When administered the solution, 5-Fu was rapidly absorbed into plasma, liver, kidney, spleen and tumor, and rapidly cleared from these tissues after 2 or 4 h. And the AUC in tumor of 5-Fu solution was significantly lower than that of the micro-device. These results indicated that 5-Fu loaded biodegradable micro-device offered a relatively high concentration and long-term delivery of the drug to the tumor site.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23179563     DOI: 10.1007/s13318-012-0111-z

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  21 in total

1.  Development of 5-fluorouracil loaded poly(acrylamide-co-methylmethacrylate) novel core-shell microspheres: in vitro release studies.

Authors:  V Ramesh Babu; Malladi Sairam; Kallappa M Hosamani; Tejraj M Aminabhavi
Journal:  Int J Pharm       Date:  2006-06-17       Impact factor: 5.875

2.  Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry.

Authors:  E Matsushima; K Yoshida; R Kitamura; K Yoshida
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1997-03-28

3.  Rapid determination of 5-fluorouracil in plasma using capillary electrophoresis.

Authors:  Hao-jie Lu; Yin-long Guo; Hong Zhang; Qing-yu Ou
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-05-25       Impact factor: 3.205

4.  Pharmacokinetics of 5-fluorouracil in rats with diabetes mellitus induced by streptozotocin.

Authors:  Young H Choi; Ae K Lee; Soo K Bae; Sun O Kim; Myung G Lee
Journal:  Biopharm Drug Dispos       Date:  2005-04       Impact factor: 1.627

5.  Simultaneous gas chromatographic-mass spectrophotometric determination of alpha-fluoro-beta-alanine and 5-fluorouracil in plasma.

Authors:  D Anderson; D J Kerr; C Blesing; L W Seymour
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1997-01-10

6.  Anti-cancer drug diffusion within living rat brain tissue: an experimental study using [3H](6)-5-fluorouracil-loaded PLGA microspheres.

Authors:  Valérie Gaëlle Roullin; Jean-Robert Deverre; Laurent Lemaire; François Hindré; Marie-Claire Venier-Julienne; Raymond Vienet; Jean-Pierre Benoit
Journal:  Eur J Pharm Biopharm       Date:  2002-05       Impact factor: 5.571

7.  Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. Nordic Gastrointestinal Tumour Adjuvant Therapy Group.

Authors:  B Glimelius; A Jakobsen; W Graf; A Berglund; C Gadeberg; P Hansen; M Kjaer; N Brunsgaard; E Sandberg; B Lindberg; H Sellström; T Lorentz; L Påhlman; B Gustavsson
Journal:  Eur J Cancer       Date:  1998-04       Impact factor: 9.162

8.  Sensitive MS/MS-liquid chromatography assay for simultaneous determination of tegafur, 5-fluorouracil and 5-fluorodihydrouracil in plasma.

Authors:  G Remaud; M Boisdron-Celle; A Morel; A Gamelin
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2005-09-25       Impact factor: 3.205

9.  Different dose regimens of 5-fluorouracil and interferon-alpha in patients with metastatic colorectal carcinoma.

Authors:  P Ragnhammar; H Blomgren; D Edler; G Lundell; I Magnusson; T Sonnenfeld
Journal:  Eur J Cancer       Date:  1995       Impact factor: 9.162

10.  Therapeutic efficacy study of novel 5-FU-loaded PMM 2.1.2-based microspheres on C6 glioma.

Authors:  E Fournier; C Passirani; A Vonarbourg; L Lemaire; N Colin; S Sagodira; P Menei; J-P Benoit
Journal:  Int J Pharm       Date:  2003-12-11       Impact factor: 5.875

View more
  3 in total

1.  Synergetic effect of SLN-curcumin and LDH-5-Fu on SMMC-7721 liver cancer cell line.

Authors:  Rongrong Zhu; Xianzheng Wu; Yu Xiao; Bo Gao; Qian Xie; Hui Liu; Shilong Wang
Journal:  Cancer Biother Radiopharm       Date:  2013-06-29       Impact factor: 3.099

2.  5-Fluorouracil blocks quorum-sensing of biofilm-embedded methicillin-resistant Staphylococcus aureus in mice.

Authors:  Ferdinand Sedlmayer; Anne-Kathrin Woischnig; Vincent Unterreiner; Florian Fuchs; Daniel Baeschlin; Nina Khanna; Martin Fussenegger
Journal:  Nucleic Acids Res       Date:  2021-07-21       Impact factor: 19.160

Review 3.  Fabrication and Use of Poly(d,l-lactide-co-glycolide)-Based Formulations Designed for Modified Release of 5-Fluorouracil.

Authors:  Nattawut Leelakanok; Sean Geary; Aliasger Salem
Journal:  J Pharm Sci       Date:  2017-10-16       Impact factor: 3.784

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.